Freja Gam Østergaard                                                                                                          

 freja

Profile Update 28.02.2019

Current activities:

I’ve currently finished all experiments of the project, and almost all the data has been analysed. There are storylines for three manuscripts, which are now in preparation (see titles under accomplishments). Hopefully, the other two can be submitted within four months.

Accomplishments:

  • Freja Gam Østergaard, Alex R. Wade, Hartwig Roman Siebner, Kenneth Vielsted Christensen and Bettina Laursen. Progressive effects of sildenafil on visual processing in rats. Neuropharmacology? 2019
  • Freja Gam Østergaard, Bettina Laursen, Marc M. Himmelberg, Tim B. Dyrby, Hartwig R. Siebner, Alex R. Wade, and Kenneth Vielsted Christensen. A visual assay for detection of α-synuclein-related pathology in a rat model of Parkinson’s Disease. eNeuro? 2019
  • Freja Gam Østergaard, Christian Skoven, Alex R. Wade, Hartwig R. Siebner, Bettina Laursen, Kenneth Vielsted Christensen & Tim B. Dyrby. Mapping visual processing with functional MRI in a rodent model of α-synuclein overexpression. Scientific Reports? 2019

Future plans:

When the thesis defence has been deemed successful, I expect to continue with a carrier in research

My NextGenVis Experience:

The NextGenVis has provided a great opportunity for expanding knowledge of visual neuroscience and methodologies. It further provided a network of capable scientists and research institutions.

======

Education

2015    MSc. in Neuroscience and Neuroimaging

Thesis: TET1 in retrieval of mCPP

Sino-Danish Center at University of Chinese Academy of Sciences in collaboration with University of Århus, China

2013    BSc. in Biomedicine with an elective in Experimental Molecular Biology

University of Southern Denmark, Denmark

 

Current project

Changes in visual processing as biomarkers for Parkinson’s Disease

-A translational study illuminating the possibility of using changes in visual processing as a biomarker for the progression of synucleinopathies, primarily focusing on Parkinson’s disease. Preliminary studies will be carried out in rats using visually-evoked potentials (VEPs).

Research Interests

Neuropharmacology, Electrophysiology, Perception